Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (69)

I-005Wouter Ahmed

Development of a mechanistic joint model describing multivariate continuous and event outcomes linked through a latent variable

Wednesday 10:30-12:00

I-020Salma Bahnasawy

Modelling antibiotic PKPD in a lung-mimicking transwell model

Wednesday 10:30-12:00

I-024Asma Baliouze

Population Pharmacokinetic and Exposure-Response Modeling of Mavacamten in Hypertrophic Cardiomyopathy: Impact of Japanese Ethnicity.

Wednesday 10:30-12:00

I-027Imke Bartelink

Comparative Evaluation Of Pharmacokinetic Models For Total And Unbound Drug Concentrations: What Is The Consensus For Modelling Nonlinear Protein Binding?

Wednesday 10:30-12:00

I-035Stéphane Bertin

Population pharmacokinetics of levosimendan and its metabolites OR-1855 and OR-1896 in critically ill adults and children on ECMO

Wednesday 10:30-12:00

I-039Laura Boles

A translational PKPD framework for the prediction of the early bactericidal activity of telacebec for the treatment of pulmonary tuberculosis.

Wednesday 10:30-12:00

I-051Kangna CAO

Predicting tissue iron distribution following intravenous ferric carboxymaltose therapy using a physiologically-based pharmacokinetic model

Wednesday 10:30-12:00

I-056Vincent Chang

Subject-level meta-analysis of obeldesivir clinical safety and pharmacokinetic data

Wednesday 10:30-12:00

I-058Jun Chen

Population Pharmacokinetic and Pharmacodynamic Modeling and Simulations of Danicopan in Combination with Eculizumab/Ravulizumab for Patients with PNH Who Have Clinically Significant Extravascular Hemolysis (CS-EVH)

Wednesday 10:30-12:00

I-065Seung Chan Choi

Demonstrating Similarity of Denosumab Biosimilar SB16 to Reference Denosumab Using Population PK-PD Modeling

Wednesday 10:30-12:00

I-068Lindsay Clegg

A validated model of the neutralising antibody-efficacy relationship for monoclonal antibody pre-exposure prophylaxis against COVID-19

Wednesday 10:30-12:00

I-075Vincent Croixmarie

Comprehensive population PK/PD modeling of perindopril, indapamide, and bisoprolol in healthy volunteers: insights for fixed-dose combination therapy in hypertension

Wednesday 10:30-12:00

I-079Huong Tra Dang

Physiological-based pharmacokinetics/pharmacodynamic modelling for Ivabradine and its major active metabolites, S18982

Wednesday 10:30-12:00

I-090Oscar Della Pasqua

Implications of credibility criteria for model-informed evidence for the evaluation and approval of medicinal products for rare/paediatric diseases: a case study on the use of chelation therapy in patients affected by transfusion dependent haemoglobinopathies.

Wednesday 10:30-12:00

I-095ALESSANDRO Di Deo

Pharmacokinetics and dose optimisation of continuous fentanyl infusion in newborns with hypoxic–ischaemic encephalopathy undergoing therapeutic hypothermia

Wednesday 10:30-12:00

II-004Alan Faraj

Characterization of concizumab exposure and the link to free tissue factor pathway inhibitor, thrombin peak, and occurrence of bleeding events

Wednesday 15:30-17:00

II-015Frédéric Gaspar

Beyond Genotype: The Added Value of CYP2C19 Phenotype on clopidogrel plasma concentrations in a hospitalized cohort using Pharmacokinetic Modeling

Wednesday 15:30-17:00

II-023Mikel Gomes

Predicting long-term weight loss using self-reported, digitally collected, real-world data after initiation of semaglutide for overweight/obesity

Wednesday 15:30-17:00

II-045Christian Hollensen

Leveraging Model-Informed Drug Development to Expedite Phase 2b Initiation for an Oral Peptide Targeting PCSK9

Wednesday 15:30-17:00

II-046Ana Homšek

Estimation of infliximab clearance in patients with acute severe ulcerative colitis prior to and after achieving clinical remission using a population pharmacokinetic modelling approach

Wednesday 15:30-17:00

II-047Miao-Chan Huang

Physiologically-based pharmacokinetic modeling to predict systemic and liver exposure to bosentan

Wednesday 15:30-17:00

II-057Nicharee Jiracheep

Population Pharmacokinetics and Dose Optimization of a Novel Triple Combination Therapy: Arterolane-Piperaquine-Mefloquine in Kenyan Children with Malaria

Wednesday 15:30-17:00

II-059Tanvi Joshi

Extending a Quantitative Systems Pharmacology model of Ulcerative Colitis to a single all-comers Virtual Population for optimizing therapeutic combinations in Phase 3 trials.

Wednesday 15:30-17:00

II-074Feras Khalil

Allometric and Population pharmacokinetic Modeling for Human Dose Prediction in a First-in-Human Trial: A Case Study with Retrospective Evaluation

Wednesday 15:30-17:00

II-076Jonas Kildegaard

Dose selection of concizumab for prophylactic treatment of bleeding episodes in haemophilia A or B with or without inhibitors

Wednesday 15:30-17:00

II-091Victoria Kulesh

Healthy aging and Immunology: A Quantitative Model-Based Meta-Analysis (MBMA) of Age-Dependent Human T-Lymphocyte Homeostasis

Wednesday 15:30-17:00

II-094Pietro Laddomada

In vitro-in vivo differences in the relationship between cangrelor concentration and platelet aggregation inhibition effect: implications for the extrapolation of efficacy from adults and dose rationale for infants and children.

Wednesday 15:30-17:00

II-096Jennifer Lang

Evaluation of GalNAc-siRNA mediated reduction of ApoC3 and triglycerides in healthy participants using a population PK/PD approach

Wednesday 15:30-17:00

II-108Raphaelle Lesage

Open-Source Quantitative Modeling of Tuberculosis Drug-Induced Cardiac Risks

Wednesday 15:30-17:00

II-112Yingxue Li

Mechanism-based Pharmacodynamic Model for the Hemodynamic effects of Norepinephrine in Healthy Volunteers

Wednesday 15:30-17:00

III-001Andreas Lindauer

Modeling Copper Kinetics in Wilson’s Disease: A Mechanistic Model to Guide Gene Therapy

Thursday 9:50-11:45

III-004Chenyao Liu

Impact of a mobile messaging service on patterns of adherence to antiepileptic medications: a model-based analysis of the SMS Trial

Thursday 9:50-11:45

III-015Julia Macente

In Vitro-To-In Vivo Extrapolation Of Drug Transfer Into Human Milk Using The Simcyp Simulator: A Contribution From The IMIc4c Conception Project.

Thursday 9:50-11:45

III-036Adrien Mitard

Exposure history shapes SARS-CoV-2 viral dynamics in Non-Human Primates and provides insights into correlates of protection against infection and transmission

Thursday 9:50-11:45

III-044Dr BC Narmada

Mechanistic Modeling of Glucagon-Like Peptide (GLP-1) Therapeutics Development for Obesity Management

Thursday 9:50-11:45

III-048Nina Nauwelaerts

Enhancing PB(P)K Models for the Female Reproductive Tract: A Framework for Local and Systemic Drug Kinetics

Thursday 9:50-11:45

III-055Emmanuel Niyigena

A Model-Informed Algorithm for Personalized Infliximab Rescue Therapy to Maximize Colectomy-Free Survival in Patients with Acute Severe Ulcerative Colitis

Thursday 9:50-11:45

III-062Qing Xi Ooi

Population pharmacokinetic-target engagement analysis of ocular and systemic data for intravitreal BI 764524 in patients with diabetic macular ischemia from the HORNBILL study

Thursday 9:50-11:45

III-069Eirini Panoilia

Pharmacokinetic-target engagement modelling of an anti-CCL17 monoclonal antibody in healthy volunteers and osteoarthritis patients

Thursday 9:50-11:45

III-071Caterina Paparsenos

Population Pharmacokinetic and Exposure-Response analyses of Tezepelumab in Phase 3 study (DIRECTION) supports no dose adjustment in Chinese Adults and Adolescents with Asthma.

Thursday 9:50-11:45

III-077Elena Pascual Garcia

Towards model-informed design of antibiotic therapies: prediction of bacterial physiology & growth in response to ribosome-targeting antibiotics.

Thursday 9:50-11:45

III-092Sebastian Polak

Using PBPK-QSP model to move the boundaries of transthyretin stabilization understanding

Thursday 9:50-11:45

III-093Vikram Prabhakar

A Quantitative Systems Pharmacology model to predict clinical Pharmacokinetics/Pharmacodynamics of various small interfering RNA therapeutics and learnings from model development

Thursday 9:50-11:45

III-098Najia Rahim

Physiologically based pharmacokinetic modeling of lamotrigine to predict drug disposition using GastroPlusTM

Thursday 9:50-11:45

III-108Maša Roganovic

Association of Adalimumab Clearance with Platelet Levels in Patients with Inflammatory Bowel Disease: A Nonlinear Mixed-Effects Modelling Approach

Thursday 9:50-11:45

III-109Rachel Rose

Applications of an Immunogenicity QSP Platform: Predictive Modelling for ADA and PK Impact for Biotherapeutic Combinations

Thursday 9:50-11:45

IV-002Eric Salgado

A population pharmacokinetic model of obeldesivir in healthy subjects and patients with COVID-19

Thursday 15:00-16:45

IV-005Harshbir Singh Sandhu

Development of a framework for mechanistic modelling and interspecies scaling for AAV gene therapy

Thursday 15:00-16:45

IV-014Carmine Schiavone

Unveiling the Kinetics of Immunity: Mechanistic Insights into COVID-19 Vaccine Responses and Population Stratification

Thursday 15:00-16:45

IV-021Erin H. Smeijsters

Population pharmacokinetic model for a local sustained-release hydrogel formulation containing bupivacaine for the postoperative pain management after spinal surgery.

Thursday 15:00-16:45

IV-022Jisoo Song

A population pharmacokinetic model of abiraterone with a mixed zero-order and first-order absorption kinetics in healthy Korean volunteers

Thursday 15:00-16:45

IV-030Julia Stolk

A Quantitative Systems Pharmacology Model to Investigate the Crucial Role of Epithelial Damage in the Pathogenesis of Inflammatory Bowel Disease

Thursday 15:00-16:45

IV-033Jérémie Tachet

Optimizing ruxolitinib therapy using a population approach: insights from a real-world prospective observational study

Thursday 15:00-16:45

IV-038Lénaïg Tanneau

Assessment of Phase 1 pharmacokinetic-pharmacodynamic predictions, based on Phase 3 clinical trials results.Depemokimab pharmacokinetics and response in blood eosinophil count reduction for asthma and chronic rhinosinusitis with nasal polyps patients

Thursday 15:00-16:45

IV-042Johannes Tillil

Patients with chronic inflammatory diseases experience higher exposure of small-molecule drugs than healthy volunteers: A population PK model-focused analysis of recently approved drugs

Thursday 15:00-16:45

IV-048Armando Tratenšek

Target-mediated drug disposition model of ustekinumab in patients with ulcerative colitis

Thursday 15:00-16:45

IV-052Anastasia Tsyplakova

Optimizing Mycophenolate Therapy in Renal Transplant Patients Using Machine Learning and Population Pharmacokinetic Modeling

Thursday 15:00-16:45

IV-057Elodie Valade

Assessment of Vactosertib effect on QT interval: A Retrospective Concentration-QTc Analysis in Oncology Patients

Thursday 15:00-16:45

IV-059Cristian Valiante

Defining Adult Dosing of Midazolam Oromucosal Solution for Prolonged Seizures Using Population PK Modeling

Thursday 15:00-16:45

IV-064Bart van Lieshout

A Model-Based Framework for Intracellular Pathogen Pharmacodynamics to Accelerate the Translation of Host-Directed Therapies

Thursday 15:00-16:45

IV-073Esmee Vendel

Integrated PK-PD model relating serum copper concentrations, urinary copper clearance and trientine pharmacokinetics in Wilson Disease: initial insights from the UNITED study

Thursday 15:00-16:45

IV-087Gustaf Wellhagen

Predictors of ability to work in multiple sclerosis

Thursday 15:00-16:45

IV-088Haini Wen

A pulmonary population PBPK model for sampling design evaluation

Thursday 15:00-16:45

IV-089Manon Wigbers

Applications of Quantitative Systems Pharmacology (QSP) Modelling for Vaccine Development

Thursday 15:00-16:45

IV-103Raiki Yoshimura

Prediction of Disease Progression in Acute Liver Injury Patients Using Machine Learning and Mathematical Modeling

Thursday 15:00-16:45

IV-106Mengxu Zhang

Predicting Clozapine Brain Extracellular Pharmacokinetics in Rat and Human: Integrating Brain Metabolism, Active Influx Transport and Accumulation in Neutral Lipids in the LeiCNS PBPK Model

Thursday 15:00-16:45

IV-109Wei Zhang

Impact of assay on the predictive performance of model-informed precision dosing of ustekinumab in patients with Crohn’s disease

Thursday 15:00-16:45

IV-110Qiaolin Zhao

Population PK Analysis of Infliximab in Young Pediatric IBD Patients: Label-Recommended Dose Fails to Achieve Therapeutic Target Concentration

Thursday 15:00-16:45

IV-112Jin Zhou

Population Pharmacokinetic Analysis of Seladelpar in Patients with Primary Biliary Cholangitis

Thursday 15:00-16:45